Summit Therapeutics Inc.

SMMT | NASDAQ

Price Alert Chart Builder DCF Calculator

$17.09

+$0.19 (+1.12%)

Sep 22, 2026, 2:47 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+1.12%

(1D)

Rating

Updated: Aug 17, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $13.63B

1D Range

16.79 17.50

52W Range

12.07 29.23

Valuation (TTM)

PE -15.09

PB 21.40

EV/EBITDA -14.97

Valuation (NTM)

Forward PE N/A

Forward PEG 6.37

Price Target $26.86

Cash Flow

FCF Yield -3.0%

SBC Adj. FCF Yield -5.4%

SBC Impact -79.1%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | -94.3%

Dil EPS 3Y | 5Y -67.4% | -3.5%

FCF 3Y | 5Y -76.7% | -56.0%

Returns

ROA -113.8%

ROE -204.3%

ROIC -134.1%

Financial Health

Net Cash

$670.29M

Current Ratio 6.96

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States a...

Sector Healthcare

Industry Biotechnology

Employees 265

IPO Date Mar 4, 2015

Website www.smmttx.com

Fiscal Year January - December

Full Company Profile

Latest News

12 hours ago · businesswire.com

HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESMO 2026

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) today noted that data from the Phase III HARMONi-GI1 trial, conducted in China and sponsored by Akeso, Inc., featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab, will be featured as part of the Presidential Symposium II at the European Society for Medical Oncology 2026 Congress (ESMO 2026) which takes place October 23–27, 2026, in Madrid, Spain. The presentation will take place on Sunday, O.

8 days ago · businesswire.com

Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) announced that updated overall survival (OS) results from the global Phase III HARMONi clinical trial featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab were presented today at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC 2026) in Seoul, Republic of Korea. As Summit previously announced on July 22, 2026, ivonescimab plus plat.

18 days ago · zacks.com

SMMT Stock Soars on NSCLC Drug Survival Data Beating Keytruda in China

Summit Therapeutics stock jumps 17% after ivonescimab showed a significant overall survival benefit over Keytruda in a China phase III lung cancer study.

19 days ago · benzinga.com

Better Cancer Therapy Than Keytruda? Summit Therapeutics Partner's Ivonescimab Outperforms in Lung Cancer Study

Summit Therapeutics Inc. (NASDAQ:SMMT) stock is trading higher on Thursday after its development partner, Akeso Inc., reported highly favorable overall survival data from a late-stage clinical trial.

26 days ago · zacks.com

SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study

Summit gains as positive HARMONi-GI1 data show ivonescimab's OS benefit in biliary tract cancer, expanding its potential beyond NSCLC.

27 days ago · seekingalpha.com

Summit Therapeutics: Signals Of Moving Past Lung Cancer (Rating Upgrade)

Summit Therapeutics, Inc. is upgraded to Buy as negative sentiment bottoms and catalysts approach, despite high volatility and cash burn. Ivonescimab demonstrated survival benefits in Chinese NSCLC and biliary tract cancer trials, with pivotal global data and FDA decisions pending. SMMT's liquidity covers 4–5 quarters, but aggressive pipeline expansion and high operating expenses raise going concern risks.

27 days ago · benzinga.com

Summit Therapeutics Partner Highlights Positive Interim Data Milestone for Lead Cancer Therapy

Summit Therapeutics Inc. (NASDAQ:SMMT) partner Akeso Inc. on Wednesday released positive topline findings from its randomized Phase 3 HARMONi-GI1 clinical trial (or AK112-309).

28 days ago · businesswire.com

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. announced positive topline results from the randomized Phase III HARMONi-GI1 study (AK112-309) evaluating ivonescimab plus chemotherapy compared with durvalumab plus chemotherapy as a first-line treatment for patients with advanced biliary tract cancer (BTC). HARMONi-GI1 is a single-region, multi-center, Phase III study conducted in China and sponsored by Akeso, with all relevant data exclusi.